TARCEVA

LOE Approaching

erlotinib hydrochloride

NDAORALTABLETPriority Review
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT03126799Phase 2Unknown

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Started Nov 2016
128 enrolled
EGFR Positive Non-small Cell Lung Cancer
NCT02157883Phase 1Completed

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Started Nov 2014
39 enrolled
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
NCT02133508N/ACompleted

A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)

Started Apr 2014
172 enrolled
Non-Small Cell Lung Cancer
NCT02091141Phase 2Completed

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Started Apr 2014
673 enrolled
NeoplasmsSolid TumorsBiliary Cancer+2 more
NCT02031744Phase 3Completed

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Started Jan 2014
530 enrolled
Non-Small Cell Lung Cancer
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.